Relative risk of major events with atenolol vs placebo

Slides:

Advertisements

Similar presentations

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Advertisements

Type 2 diabetes and high blood pressure How explosive is the cocktail?

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Randomized, double-blind, multicenter, controlled trial.

RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med 2006; available at: End pointActive therapy PlaceboRelative.

Participant Characteristics by Lowest Leg AAI Category Ann M. O’Hare, et al, Circulation 2006;113;

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

LEADER trial: Primary Outcome

HOPE: Heart Outcomes Prevention Evaluation study

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

The Anglo Scandinavian Cardiac Outcomes Trial

Scandinavian Simvastatin Survival Study (4S)

TNT: Baseline and final LDL cholesterol levels

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Relative mortality risk associated with quartiles of systolic blood pressure compared with systolic

Adjusted relative mortality risk

Baseline characteristics of patients

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

LIFE: Reduction in primary end-point events seen with reduction of LVH by two electrocardiographic criteria End point % reduction with each 1050-mm x ms.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

ASCOT-BPLA: Primary and secondary end points

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Jun M, et al. Lancet 2010 Epub May 10

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Fung TT, et al. Circulation 2009;119:

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

β-Blockers in Heart Failure: Breaking Tradition to Avoid Diabetes?

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p for noninferiority < 0.001)

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Cystatin C levels and risk of death from all causes

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Patient characteristics: American vs Canadian transplant patients

Berger JS, et al. JAMA 2009;301:

Risk of mortality and fatal and nonfatal cardiovascular events in highest vs lowest quartiles for troponin T End point Relative risk 95% CI p Mortality.

Cause of death Treatment-arm events, % (n=45 054)

DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.

Baseline Characteristics by hs-CRP

UK paediatric cardiac surgery mortality rate by year for all cases and total number of procedures performed between 2000 and 2009/2010. UK paediatric cardiac.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

MATRIX: Radial vs. Femoral

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Standard mean difference of change in creatinine between the intravenous (IV) versus oral (PO) arm. Standard mean difference of change in creatinine between.

Absolute mortality difference Change in LVEF from baseline

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Difference in the risk of MACEs in patients treated with anti-IL23 agents compared with the placebo in RCTs. IL, interleukin; MACEs, major adverse cardiovascular.

FIELD: Primary outcome

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Outcomes Group Number of events Total person-years aIRR (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Outcomes Number of events† Total person-years† aHR‡ (95%CI)

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Presentation transcript:

Relative risk of major events with atenolol vs placebo End point Relative risk 95% CI All-cause mortality 1.01 0.89-1.15 Cardiovascular mortality 0.99 0.83-1.18 MI 0.83-1.19 Stroke 0.85 0.72-1.01 Carlberg B et al. Lancet 2004; 364:1684–1689.

Relative risk of major events with atenolol vs other antihypertensive drugs End point Relative risk 95% CI All-cause mortality 1.13 1.02-1.25 Cardiovascular mortality 1.16 1.00-1.34 MI 1.04 0.89-1.20 Stroke 1.30 1.12-1.50 Carlberg B et al. Lancet 2004; 364:1684–1689.